UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

UCB, a global biopharmaceutical company, today presented positive efficacy and safety results from the GEMZ phase 3 study ...

(PR) UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

The MarketWatch News Department was not involved in the creation of this content.-- Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a stati ...
The Malaysian Reserve

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure ...

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in co ...
Frontiers

Gut microbiota metabolites in the immunoregulation of enteritis: research progress

1 Department of Emergency and Critical Care Medicine, Chuzhou Integrated Traditional Chinese and Western Medicine Hospital, Chuzhou, Anhui, China 2 Department of Gastroenterology, The First Affiliated ...